Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).

Published

Journal Article

Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.

Full Text

Duke Authors

Cited Authors

  • Rebeiz, AG; Dery, J-P; Tsiatis, AA; O'shea, JC; Johnson, BA; Hellkamp, AS; Pieper, KS; Gilchrist, IC; Slater, J; Muhlestein, JB; Joseph, D; Kitt, MM; Tcheng, JE; ESPRIT substudy,

Published Date

  • October 2004

Published In

Volume / Issue

  • 94 / 7

Start / End Page

  • 926 - 929

PubMed ID

  • 15464679

Pubmed Central ID

  • 15464679

Electronic International Standard Serial Number (EISSN)

  • 1879-1913

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2004.06.030

Language

  • eng